FDG Digital PET/CT as First Line Investigation for Giant Cell Arteritis

Status Recruiting

Clinical Trial Summary

Giant cell arteritis (GCA) causes inflammation of the arteries and can lead to serious complications such as blindness, necessitating rapid diagnosis and treatment. Although older technology non-digital PET/CT scans are routinely used for the diagnosis of GCA in large arteries, they have not been able to reliably detect inflammation of the small arteries responsible for blindness. Recent technological advances have enabled PET/CT imaging of millimetric disease in the body, which are now able to resolve small arteries. In the proposed research study, patients who are suspected by their doctors to have GCA will undergo an ultrasound of the temporal arteries, and digital PET/CT scan after injection of radioactive glucose. Digital PET/CT scans will be interpreted for the presence of abnormal uptake in the large and small arteries, as well as for the presence of other causes of the patient's symptoms. The diagnostic accuracy of PET/CT and ultrasound will be evaluated with respect to an expert panel diagnosis of giant cell arteritis and compared. Results will be adjusted for lack of a perfect reference test using advanced statistics. The goal will be to see if digital PET/CT can become a single, integrated test to diagnose this disease.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05000138
Study type	Observational
Source	Jewish General Hospital
Contact	Gad Abikhzer, MD
Phone	514-340-8222
Email	gad.abikhzer@mcgill.ca
Status	Recruiting
Phase
Start date	June 10, 2022
Completion date	June 30, 2025

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT03812302` - Use of Gallium-68 HA-DOTATATE PET/CT in Giant Cell Arteritis (GCA)	Phase 2
Recruiting	`NCT02257866` - Studies of the Natural History, Pathogenesis, and Outcome of Idiopathic Systemic Vasculitis
Recruiting	`NCT04888221` - Efficacy of Tocilizumab in Association to Steroids in Giant Cell Arteritis With Cerebro-vascular Involvement	Phase 3
Recruiting	`NCT05380453` - Efficacy and Safety of Secukinumab in Patients With New Onset of Giant Cell Arteritis Who Are in Clinical Remission	Phase 3
Recruiting	`NCT02333708` - Study of Circulating Microparticles in Giant Cell Arteritis
Completed	`NCT01450137` - Tocilizumab for Patients With Giant Cell Arteritis	Phase 2
Completed	`NCT03827018` - KPL-301 for Subjects With Giant Cell Arteritis	Phase 2
Active, not recruiting	`NCT04519580` - Improved Diagnostics and Monitoring of Polymyalgia Rheumatica
Recruiting	`NCT04239196` - Efficacy of Tocilizumab for the Treatment of Acute AION Related to GCA	Phase 2
Completed	`NCT03202368` - An Extension Study to Evaluate Long-Term Safety of Subcutaneous (SC) Tocilizumab in Participants With Giant Cell Arteritis (GCA)	Phase 3
Not yet recruiting	`NCT06004154` - Post-therapeutic Imaging Evaluation of Patients With Horton's Disease (Giant Cell Arteritis) (EvHortim)
Not yet recruiting	`NCT02523625` - Giant Cell Arteritis: Improving Use of Ultrasound Evaluation	N/A
Completed	`NCT03285945` - FDG Uptake in Large-Vessel Giant Cell Arteritis After Short-term, High-Dose Steroid Treatment	N/A
Completed	`NCT02190916` - Vasculitis Illness Perception (VIP) Study	N/A
Recruiting	`NCT01241305` - One-Time DNA Study for Vasculitis
Terminated	`NCT02531633` - Efficacy and Safety Study of Sirukumab in Patients With Giant Cell Arteritis	Phase 3
Completed	`NCT03409913` - Diagnostic Accuracy of FDG PET/CT of Cranial Arteries in GCA	N/A
Completed	`NCT03765424` - Evaluation of Ultrasound and PET/CT in the Diagnosis and Monitoring of Giant Cell Arteritis
Completed	`NCT01910038` - Evaluation of Tocilizumab as an add-on Therapy to Corticoids in Giant Cell Arteritis: Proof of Concept Study.	Phase 2
Not yet recruiting	`NCT04012905` - Giant Cell Arteritis: Comparison Between Two Standardized Corticosteroids Tapering	Phase 3